Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziga Rotar

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Arthritis Care & Research|June 26, 2024
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European CountriesLouise Linde, Stylianos Georgiadis, Lykke M Ørnbjerg, et al.
BMC Rheumatology|July 2, 2025
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation studyStylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, et al.
RMD Open|February 20, 2025
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritisStylianos Georgiadis, Marion Pons, Simon Rasmussen, et al.
BMC Medical Research Methodology|February 28, 2025
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiasedChristos Polysopoulos, Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, et al.
The Journal of Rheumatology|January 15, 2024
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine CareLykke M Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
EULAR Rheumatology Open|June 29, 2026
The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patientsZohra Faizy Ahmadzay, Stylianos Georgiadis, Mikkel Østergaard, et al.
Rheumatology (Oxford, England)|March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritisMichael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
Rheumatology (Oxford, England)|June 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registriesLouise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Arthritis Care & Research|June 26, 2024
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European CountriesLouise Linde, Stylianos Georgiadis, Lykke M Ørnbjerg, et al.
BMC Rheumatology|July 2, 2025
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation studyStylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, et al.
RMD Open|February 20, 2025
Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritisStylianos Georgiadis, Marion Pons, Simon Rasmussen, et al.
BMC Medical Research Methodology|February 28, 2025
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiasedChristos Polysopoulos, Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, et al.
The Journal of Rheumatology|January 15, 2024
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine CareLykke M Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
EULAR Rheumatology Open|June 29, 2026
The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patientsZohra Faizy Ahmadzay, Stylianos Georgiadis, Mikkel Østergaard, et al.
Rheumatology (Oxford, England)|March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritisMichael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
Rheumatology (Oxford, England)|June 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registriesLouise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
Pageof 7